XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE AND SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2025
REVENUE AND SEGMENT INFORMATION  
Schedule of disaggregation of revenue

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended March 31, 2025:

Distributors/

    

Direct

    

Strategic Partners

    

Total

Product revenue:

 

  

 

  

 

  

United States

$

62,607

$

$

62,607

Germany

 

2,796,237

2,796,237

All other countries

 

1,889,370

3,979,024

5,868,394

 

Product revenue

$

4,748,214

$

3,979,024

$

8,727,238

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended March 31, 2024:

Distributors/

    

Direct

    

Strategic Partners

    

Total

Product revenue:

 

  

 

  

 

  

United States

$

21,616

$

18,000

$

39,616

Germany

 

3,537,727

3,537,727

All other countries

 

1,750,541

3,661,636

5,412,177

 

Product revenue

$

5,309,884

$

3,679,636

$

8,989,520

Schedule of receivables and contract liabilities from contracts with customers

    

March 31, 2025

    

December 31, 2024

Contract receivables, which are included in grants and accounts receivable

$

5,861,678

$

4,426,890

Contract liabilities, which are included in accrued expenses and other current liabilities

$

729,742

$

596,042

Schedule of segment information

    

Three Months Ended

 

March 31,

 

2025

2024

 

Product revenue

$

8,727,238

$

8,989,520

Gross profit

$

6,207,597

$

6,873,610

Gross margin

 

71

%

 

76

%

Total operating expenses

$

10,094,805

$

11,529,978

EBITDA and Adjusted EBITDA (both non-GAAP measures):

 

  

 

  

Net loss attributable to common stockholders

$

(1,478,358)

$

(6,088,711)

Interest expense, net

 

605,134

 

6,653

Benefit from income taxes

 

 

Depreciation and amortization expense

 

368,503

 

397,286

Loss before interest expense, income taxes, depreciation and amortization (“EBITDA”), a non-GAAP measure

 

(504,721)

 

(5,684,772)

Stock-based compensation

 

818,426

 

959,465

Loss (gain) on foreign currency transactions

(3,013,984)

 

1,425,690

Adjusted EBITDA, a non-GAAP measure

$

(2,700,279)

$

(3,299,617)

Adjusted net loss, a non-GAAP measure:

 

  

 

  

Net loss attributable to common stockholders

$

(1,478,358)

$

(6,088,711)

Stock-based compensation

 

818,426

 

959,465

Loss (gain) on foreign currency transactions

(3,013,984)

1,425,690

Adjusted net loss, a non-GAAP measure

$

(3,673,916)

$

(3,703,556)

Total cash used in operating and investing activities

$

(3,512,197)

$

(4,956,777)

    

March 31, 2025

    

December 31, 2024

Total assets

$

50,781,684

$

47,371,500

    

Three Months Ended    

March 31,

2025

2024

Research and development:

 

  

 

  

Clinical expenses

$

979,113

$

1,627,449

Other research and development expenses

 

683,812

 

619,462

Total research and development

$

1,662,925

$

2,246,911

Selling, general and administrative

 

  

 

  

Royalty expense

 

257,883

 

712,385

Stock-based compensation

 

626,641

 

959,465

Legal, financial and consulting

 

637,981

 

680,706

Other general and administrative

 

6,909,375

 

6,930,511

Total selling, general and administrative

$

8,431,880

$

9,283,067